Group items tagged

Unmet needs in hematologic malignancies calls for companies focusing on PI3Ks and BTK inhibitors to offer better treatment options. Around USD 10 bn has already been invested in licensing and acquisition of PI3K and other kinase inhibitors since the last five years. Targeting kinases have been on the agenda of most drug developers as they hold the key path to signaling, development and growth of the cell. Large global pharma are constantly on the hunt for drugs with label expansion potential, longevity and blockbuster potential.

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.